[Immune checkpoints inhibitors: Recent data from ASCO's meeting 2017 and perspectives].
Fiche publication
Date publication
juin 2018
Journal
Bulletin du cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Dr VIGNOT Stéphane
Tous les auteurs :
Kfoury M, Disdero V, Vicier C, Le Saux O, Gougis P, Sajous C, Vignot S
Lien Pubmed
Résumé
Immune checkpoint inhibitors anti-PD-1, anti-PD-L1 and anti-CTLA-4 have been in development in several indications and have changed the face of cancer patients' management. Cancer immunotherapy was central in ASCO's meeting 2017. The identification of patients who could benefit most from immune checkpoint inhibitors is essential. The predictive value of PD-L1 status remains insufficient to select patients who could respond to immunotherapy. An extended search for new biomarkers predictive of response (INF-γ, mutational load) is ongoing, in order to better select responders. Immune checkpoint inhibitors have mainly been developed as monotherapy. However, the low response rate, between 10 and 30%, and the occurrence of resistance, contributes to the increment of new therapeutic strategies. This review summarizes the results of combination trials of two immune checkpoint inhibitors, combination of immunotherapy with conventional chemotherapy, radiotherapy or targeted therapies active on the oncogenic addiction pathway.
Mots clés
Biomarkers, Biomarqueurs, Combinaisons, Combinations, Immune checkpoint inhibitors, Immunotherapy, Immunothérapie, Inhibiteurs de checkpoints immunitaires, PD-1/PD-L1
Référence
Bull Cancer. 2018 06 20;105(7-8):686-695